Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX)
CUSIP: 00972G207
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Ordinary Shares, $0.000000005 par value
- Shares outstanding
- 94,284,567,045
- Total 13F shares
- 1,170,067
- Share change
- +619,327
- Total reported value
- $1,181,319
- Price per share
- $1.01
- Number of holders
- 16
- Value change
- +$593,371
- Number of buys
- 5
- Number of sells
- 5
Quarterly Holders Quick Answers
What is CUSIP 00972G207?
CUSIP 00972G207 identifies AKTX - Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 00972G207:
Top shareholders of AKTX - Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| SABBY MANAGEMENT, LLC |
13F
|
Company |
0%
|
179,785
|
$210,330 | — | 30 Jun 2025 | |
| Palo Alto Investors LP |
13F
|
Company |
0%
|
146,024
|
$170,834 | — | 30 Jun 2025 | |
| HighTower Advisors, LLC |
13F
|
Company |
0%
|
79,236
|
$92,698 | — | 30 Jun 2025 | |
| Omnia Family Wealth, LLC |
13F
|
Company |
0%
|
62,690
|
$73,341 | — | 30 Jun 2025 | |
| Cerity Partners LLC |
13F
|
Company |
0%
|
23,643
|
$27,660 | — | 30 Jun 2025 | |
| Cresset Asset Management, LLC |
13F
|
Company |
0%
|
18,408
|
$21,536 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0%
|
17,415
|
$20,374 | — | 30 Jun 2025 | |
| Accent Capital Management, LLC |
13F
|
Company |
0%
|
10,000
|
$11,699 | — | 30 Jun 2025 | |
| NewEdge Advisors, LLC |
13F
|
Company |
0%
|
6,800
|
$7,955 | — | 30 Jun 2025 | |
| EverSource Wealth Advisors, LLC |
13F
|
Company |
0%
|
4,377
|
$5,121 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
2,154
|
$2,520 | — | 30 Jun 2025 | |
| Torsten Hombeck |
3/4/5
|
CFO |
—
mixed-class rows
|
200,400
mixed-class rows
|
$468 | — | 20 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
150
|
$175 | — | 30 Jun 2025 | |
| Truvestments Capital LLC |
13F
|
Company |
0%
|
50
|
$59 | — | 30 Jun 2025 | |
| Cornerstone Planning Group LLC |
13F
|
Company |
0%
|
5
|
$5 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
3
|
$4 | — | 30 Jun 2025 | |
| Rachelle Suzanne Jacques |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
1,018,027,792
|
— | — | 26 Apr 2024 | |
| Wendy F. Dicicco |
3/4/5
|
Interim CFO |
—
class O/S missing
|
158,473,915
|
— | — | 01 May 2024 | |
| Donald A. Williams |
3/4/5
|
Director |
—
mixed-class rows
|
25,000,000
mixed-class rows
|
— | — | 28 Jun 2024 | |
| Michael Grissinger |
3/4/5
|
Director |
—
mixed-class rows
|
25,000,000
mixed-class rows
|
— | — | 28 Jun 2024 | |
| Mohamed Wa'El Ahmed Hashad |
3/4/5
|
Director |
—
class O/S missing
|
5,000,000
|
— | — | 28 Jun 2024 |
Institutional Holders of Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX) as of Q3 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.